Total Payments
$2,789
2024 Payments
$2,000
Companies
7
Transactions
21
Medicare Patients
2,124
Medicare Billing
$186,981
Payment Breakdown by Category
Research$2,261 (81.0%)
Food & Beverage$342.70 (12.3%)
Education$185.92 (6.7%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2,261 | 15 | 81.0% |
| Food and Beverage | $342.70 | 4 | 12.3% |
| Education | $185.92 | 2 | 6.7% |
Payments by Type
Research
$2,261
15 transactions
General
$528.62
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $1,873 | 14 | $0 (2024) |
| Novo Nordisk AS | $388.10 | 1 | $0 (2023) |
| Abbott Laboratories | $149.97 | 1 | $0 (2021) |
| Lilly USA, LLC | $132.32 | 2 | $0 (2023) |
| Tandem Diabetes Care, Inc. | $119.01 | 1 | $0 (2023) |
| Dexcom, Inc. | $96.31 | 1 | $0 (2024) |
| Novo Nordisk Inc | $31.01 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,000 | 16 | ABBVIE INC. ($1,873) |
| 2023 | $603.48 | 3 | Novo Nordisk AS ($388.10) |
| 2021 | $149.97 | 1 | Abbott Laboratories ($149.97) |
| 2017 | $35.95 | 1 | Lilly USA, LLC ($35.95) |
All Payment Transactions
21 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/25/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $96.31 | General |
| Category: Endocrinology | ||||||
| 06/04/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $31.01 | General |
| 04/13/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $659.60 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/13/2024 | ABBVIE INC. | — | — | In-kind items and services | $42.00 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism | ||||||
| 04/12/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $226.86 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/12/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $69.00 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/12/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $50.54 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/12/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $37.50 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/11/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $226.86 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/11/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $125.05 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/11/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $70.25 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/11/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $50.54 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/11/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $37.50 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/11/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $25.00 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/10/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $226.86 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/10/2024 | ABBVIE INC. | — | — | In-kind items and services | $25.00 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism | ||||||
| 11/12/2023 | Novo Nordisk AS | Ozempic (Drug) | — | In-kind items and services | $388.10 | Research |
| Study: NN SELECT Results Meeting Philadelphia • Category: Diabetes | ||||||
| 06/15/2023 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | Cash or cash equivalent | $96.37 | General |
| Category: Diabetes | ||||||
| 04/20/2023 | Tandem Diabetes Care, Inc. | t:slim X2 Insulin Pump with Control-IQ (Device) | Food and Beverage | In-kind items and services | $119.01 | General |
| Category: Endocrinology | ||||||
| 02/08/2021 | Abbott Laboratories | FreeStyle Lite system (Device) | Education | In-kind items and services | $149.97 | General |
| Category: Diabetes Care | ||||||
| 05/22/2017 | Lilly USA, LLC | — | Education | In-kind items and services | $35.95 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism | ABBVIE INC. | $1,873 | 14 |
| NN SELECT Results Meeting Philadelphia | Novo Nordisk AS | $388.10 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 559 | 665 | $152,398 | $50,443 |
| 2022 | 6 | 623 | 754 | $106,172 | $55,108 |
| 2021 | 9 | 501 | 565 | $96,725 | $47,212 |
| 2020 | 7 | 441 | 561 | $71,885 | $34,218 |
Total Patients
2,124
Total Services
2,545
Medicare Billing
$186,981
Procedure Codes
41
All Medicare Procedures & Services
41 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 132 | 174 | $68,902 | $23,666 | 34.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 103 | 115 | $33,589 | $10,445 | 31.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 33 | 33 | $13,833 | $4,257 | 30.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 23 | 23 | $11,960 | $3,833 | 32.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 45 | 45 | $5,130 | $2,142 | 41.7% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2023 | 52 | 72 | $6,260 | $1,939 | 31.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 27 | 27 | $3,429 | $1,703 | 49.7% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 86 | 117 | $2,925 | $1,114 | 38.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 13 | 13 | $2,796 | $732.20 | 26.2% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Facility | 2023 | 18 | 18 | $2,034 | $422.55 | 20.8% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 11 | 12 | $1,428 | $138.24 | 9.7% |
| 82962 | Blood glucose (sugar) test performed by hand-held instrument | Office | 2023 | 16 | 16 | $112.00 | $51.36 | 45.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 223 | 262 | $29,868 | $19,374 | 64.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 148 | 173 | $21,971 | $15,992 | 72.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 63 | 82 | $18,040 | $6,594 | 36.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 43 | 53 | $14,921 | $6,012 | 40.3% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Facility | 2022 | 59 | 90 | $10,170 | $2,508 | 24.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 36 | 36 | $2,772 | $1,666 | 60.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 14 | 14 | $2,170 | $1,344 | 62.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 15 | 15 | $1,850 | $650.26 | 35.1% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2022 | 11 | 18 | $2,034 | $519.30 | 25.5% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Facility | 2022 | 11 | 11 | $2,376 | $449.12 | 18.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 131 | 145 | $19,234 | $12,962 | 67.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 145 | 168 | $19,048 | $11,858 | 62.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 38 | 48 | $19,200 | $6,567 | 34.2% |
About Dr. John Poremba, M.D
Dr. John Poremba, M.D is a Endocrinology, Diabetes & Metabolism healthcare provider based in Nashua, New Hampshire. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/31/2005. The National Provider Identifier (NPI) number assigned to this provider is 1104829506.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Poremba, M.D has received a total of $2,789 in payments from pharmaceutical and medical device companies, with $2,000 received in 2024. These payments were reported across 21 transactions from 7 companies. The most common payment nature is "" ($2,261).
As a Medicare-enrolled provider, Poremba has provided services to 2,124 Medicare beneficiaries, totaling 2,545 services with total Medicare billing of $186,981. Data is available for 4 years (2020–2023), covering 41 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism|Endocrinology, Diabetes & Metabolism
- Location Nashua, NH
- Active Since 05/31/2005
- Last Updated 02/21/2023
- Taxonomy Code 207RE0101X
- Entity Type Individual
- NPI Number 1104829506
Products in Payments
- ARMOUR THYROID (Drug) $1,806
- Ozempic (Drug) $388.10
- FreeStyle Lite system (Device) $149.97
- t:slim X2 Insulin Pump with Control-IQ (Device) $119.01
- MOUNJARO (Drug) $96.37
- Dexcom G6 Transmitter (Medical Supply) $96.31
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Endocrinology, Diabetes & Metabolism Doctors in Nashua
Paul Labinson, D.o, D.O
Endocrinology, Diabetes & Metabolism — Payments: $10,087
Endocrinology, Diabetes & Metabolism $10,087
Elizabeth Jane Spatola, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $994.66
Endocrinology, Diabetes & Metabolism $994.66
Dr. Simona Ioja, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $490.20
Endocrinology, Diabetes & Metabolism $490.20
Dr. Mikhail Signalov, D.o, D.O
Endocrinology, Diabetes & Metabolism — Payments: $354.51
Endocrinology, Diabetes & Metabolism $354.51
Ellie Chuang, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $337.40
Endocrinology, Diabetes & Metabolism $337.40
Robert Levine, M.d., Face, M.D., FACE
Endocrinology, Diabetes & Metabolism — Payments: $65.19
Endocrinology, Diabetes & Metabolism $65.19